Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly)... Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -3.52 | -4.97175141243 | 70.8 | 71.29 | 66.7401 | 2334629 | 69.45757057 | CS |
| 4 | 2.33 | 3.58737490377 | 64.95 | 71.29 | 63.925 | 2165750 | 67.8074543 | CS |
| 12 | 7.13 | 11.8536990856 | 60.15 | 71.29 | 53.56 | 2048305 | 62.81035819 | CS |
| 26 | -1.3 | -1.89559638379 | 68.58 | 76.92 | 53.56 | 1870053 | 65.71611452 | CS |
| 52 | 3.91 | 6.1701120404 | 63.37 | 83.95 | 53.56 | 2005301 | 66.66056346 | CS |
| 156 | -6.91 | -9.31392370939 | 74.19 | 86.29 | 50.27 | 1911766 | 65.82884143 | CS |
| 260 | -42.18 | -38.5346245204 | 109.46 | 111.05 | 50.27 | 1715820 | 70.30431403 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
